Mesoblast Limited announced that it has appointed Jane Bell to its Board of Directors. Ms. Bell is a banking and finance lawyer with 22 years of corporate finance expertise focussing on international investment transactions in the United States, Canada, Australia and the United Kingdom, including funds management, mergers, acquisitions, and divestments. She has served as a non-executive Director in a diverse range of highly regulated sectors including delivery of healthcare, life sciences, medical research, and funds management.

Ms. Bell currently serves as Deputy Chair of Monash Health. From 2014 until 2021 she was a director of U Ethical, Australia's first ethical funds manager with over $1.2 Billion of funds under management, and a member of its Investment Committee. She has also been a director of Hudson Institute of Medical Research, is currently a director of Amplia Therapeutics, and Chairs Advisory Groups for the Royal Australian and New Zealand College of Obstetricians and Melbourne Genomics Health Alliance.

In other board changes, Shawn Tomasello will retire after four years on the Board.